U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269639) titled 'Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma' on Nov. 25.
Brief Summary: This trial is a proof-of-concept, pilot study, phase I/II clinical trial aimed at generating preliminary data on the combination of golcadomide, poseltinib, and rituximab.
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Large B-Cell Lymphoma (LBCL)
Intervention:
DRUG: Golcadomide + Poseltinib + Rituximab
Participants will receive 0.4 mg of golcadomide once daily for 14 consecutive days for 18 cycles in 28-day cycles. The first 6 cycles will be administered in combination with rituximab ...